Mycophenolate mofetil for myasthenia gravis: An open-label pilot study

Neurology

Volumn 56, Issue 1, 2001, Pages 97-99

  Ciafaloni, E ^a   Massey, J M ^a   Tucker Lipscomb, B ^a   Sanders, D B ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; CELL PROLIFERATION; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; PILOT STUDY; PRIORITY JOURNAL; PURINE SYNTHESIS; T LYMPHOCYTE ACTIVATION;

EID: 0035830461     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.56.1.97     Document Type: Article

References (9)

1. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF)
2. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection
3. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients
4. A review of clinical experience with the novel immunosuppressive drug mycophenolate mofetil in renal transplantation
5. Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation
6. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil
7. Myasthenia gravis: Recommendations for clinical research standards
8. Reliability testing of the quantitative myasthenia gravis score
9. Myasthenia gravis activities of daily living profile